EBOVAC2: Development of a Prophylactic Ebola Vaccine Using an Heterologous Prime Boost Regimen Phase II So...
CENTRE MURAZ
participó en un
H2020:
H2020-JTI-IMI2-2014-02-single-stage
The main objective therefore of EBOVAC 2 is to provide extensive and robust data on the safety, immunogenicity and efficacy of the Ad26.ZEBO...
2015-03-06 - 2021-05-31 | Financiado
2015-03-06 - 2021-05-31 | Financiado
COSMIC: Community based scheduled screening and treatment of malaria in pregnancy for improved maternal and...
CENTRE MURAZ
participó en un
FP7:
Pregnant women are very susceptible to malaria infection and Malaria in Pregnancy (MiP) is a major cause of maternal anaemia and low birth w...
Financiado
Financiado
MALACTRES: Multi drug resistance in malaria under combination therapy Assessment of specific markers and devel...
CENTRE MURAZ
participó en un
FP7:
This project aims to assess specific P. falciparum genetic markers for resistance to artemisinin-based combinations (ACT), and to develop in...
Financiado
Financiado
* No se disponen de datos de la empresa actual.